Sirona Biochem (SBM:tsxv) Investor Event
Sirona met with Investors and Brokers at Canaccord in Vancouver on September 15th, 2015.
This is the most recent corporate presentation that was put together for this recent Investor Event. You will find current collaborations, what they have in the pipeline, and the revenue growth potential.
Sirona’s presentation also reveals why management is so excited about its next major transaction.
Sirona Biochem Corp. is a biotechnology company with an innovative platform of fluorination chemistry technology. This platform is used to develop safer, more effective cosmetic and pharmaceutical active ingredients, which are licensed to partners in exchange for upfront, milestone and royalty payments. Sirona’s pipeline has produced licensing deals with Valeant Pharmaceuticals and Fosun Pharma.
- Published in Blog, Life Sciences
International Wastewater Systems’ £4million Project at Scotland’s Borders College has Begun
SHARC gets teeth into college
Work is currently underway at Borders College’s campus at Netherdale in Galashiels on a project that will see its buildings heated using sewage.
SHARC Energy Systems is the UK-based subsidiary partner of International Waste Water Heat Exchange Inc. (IWHES) based in Canada.
SHARC has secured a £4million investment from Equitix and the UK Green Investment Bank plc (GIB) to finance the installation of the SHARC sewage heat recovery system under heat purchase agreements.
The Equitix-managed fund Energy Saving Investments (ESI), in which GIB is a cornerstone investor, is investing £2m in the programme and an additional £2m of private sector capital has been mobilised from the Equitix Energy Efficiency Fund (EEEF).
This is now being used to support the first project at Borders College and a pipeline of others being developed across Scotland. The first scheme will see waste water from Scottish Water’s network used for the heat recovery system.
Commenting recently on the deal, SHARC chief executive Russ Burton said the flagship installation at Borders College involved a 20-year contract between the college and the company, making it the first organisation to adopt the world-leading technology in the UK.
“It also represents a major step forward in its heat production and energy efficiency targets for the entire campus,” he added.
Borders College, with 5,500 students, has entered into a Heat Purchase Agreement with SHARC, which means the college will purchase their heat from SHARC at a discount to gas prices that will be sustained for an extended period.
The system that has been designed for the college will deliver 95{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of all its heat requirements.
SHARC has worked with Scottish Water to enable sewage to be intercepted from its network in the Galashiels area. The scheme has been developed in such a way as to not impact on the normal operation of the sewerage network and enable the downstream waste water treatment process to continue working effectively.
Additional automatic monitoring has been built into the system by Scottish Water which, using its water resources, helps support the development of renewable energy, economic growth and sustainable technologies.
The SHARC sewage heat recovery system is already installed in numerous locations across Canada and North America. Unique in the UK and Europe, the system generates energy-saving, cost-effective and environmentally-friendly solutions for heating, cooling and hot water by extracting heat from waste water and sewage.
SHARC installs the equipment and then sells the energy back to the customer through heat purchase agreements.
Lord Smith of Kelvin, chairman of UK Green Investment Bank, said: “We are backing the deployment of innovative new technology across the UK to produce renewable energy, cut energy use, cut costs and improve the UK’s green performance.
“It is enabling SHARC Energy systems to equip Borders College with pioneering technology in an arrangement I hope can be replicated elsewhere in the country.”
IIROC Trade Resumption – DST
Canada NewsWire
TORONTO, Sept. 16, 2015
TORONTO, Sept. 16, 2015 /CNW/ – Trading resumes in:
Company: Dundee Sustainable Technologies Inc.
CSE Symbol: DST (all issues)
Resumption (ET): 09:30AM(ET)
IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions
IIROC Inquiries 1-877-442-4322 (Option 2) – Please note that IIROC is not able to provide any additional information regarding a specific trading halt. Information is limited to general enquiries only.Copyright CNW Group 2015
- Published in Dundee Sustainable Technologies
Invictus MD’s (IMH:CSE) Unit to Release New Garden Products
FUTURE HARVEST DEVELOPMENT RELEASES NEW PRODUCTS
Invictus MD Strategies Corp. is providing an update on Future Harvest Development Ltd., of which Invictus MD owns 60 per cent, and its newly expanded lineup of products for the fall season.
Wicking Gardens
This year Future Harvest has released a new line-up of wicking gardens to the market, including the Chili Grow, Herb Grow, and Duo Grow Gardens. These gardens contain smart reservoirs that contain between 7-12 liters of water and the feeder mats in each pot pull water up directly to the roots only when water is needed. This method ensures that roots are never water logged or overly dry, resulting in a continual flow of oxygen.
These wicking gardens will increase the size of your harvest on average by 2 times compared to those produced with regular pots or growbags. The increased harvest is a direct result of having optimal root conditions throughout its life.
Micro Grow Light Garden
Fresh off the success of the critically acclaimed Grow Light Garden, Future Harvest has developed and launched a garden that is half the size of the original, the ‘Micro Grow Light Garden’. This new ultra compact size and shape is ideal for table or kitchen counter-top use. The sturdy base and tray acts as a reservoir for water. In this tray sits a stand covered by a sheet of absorbent cloth that draws water up and into the bottoms of the planted seed trays by capillary action.
Included in the Micro Grow Light Garden are Sunblaster 6400K T5HO fluorescent tube lighting and a curved reflector hood that floods the growing area in full spectrum light, while using 20{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} less electricity than traditional lighting systems. The height of the hood is fully adjustable, and is secured with new adjusting collars.
The Micro Grow Light Garden is available in original black or white, and is perfect for the home, office or restaurant. Travis Brown, Sales Manager of Future Harvest commented, “Urban farming and gardening is becoming increasingly popular and these wicking gardens are perfect for this quickly growing market. Future Harvest has received excellent customer feedback and reviews on the gardens thus far, and we look forward to continual growth as the industry strengthens and demand continues to rise.”
Calnesium Nutrient Boost
Calnesium is the newest addition to Future Harvest’s Plantlife Products complete hydroponic fertilizer line. Calnesium is a powerful blend of Nitrogen, Calcium and Magnesium that is specifically designed to provide an additional nutrient boost from our 3 part hydroponic fertilizer for crops that demand it, and is an excellent additive to prevent blossom end rot on tomatoes. Canlesium can also be used as foliar spray for high value crops.
For more information on any of our products please visit www.futureharvest.com.
The Company also announces that it has settled outstanding debt of $14,300 as owed to one creditor, through the issuance of 114,400 common shares at a deemed price of $0.125 per share. The shares are subject to a hold period and may not be traded until January 16, 2016.
Sirona Biochem Reaches Major Milestone by Successful Scale-Up of Skin Lightening Compound SBM-TFC-1067
Vancouver, British Columbia – September 15, 2015 – Sirona Biochem Corp. (TSX-V: SBM, Frankfurt: ZSB, Xetra®: ZSB.DE) (the “Company”) is pleased to announce the successful scale-up of its skin lightening compound SBM-TFC-1067 (“1067”).
Sirona Biochem commissioned its contract research organization (CRO) Roowin (www.roowin.com) for the scale-up of 1 kg of 1067 compound. The successful scale-up represents a major scientific breakthrough by Sirona’s laboratory in Rouen, France. A quantity of 200 grams of 1067 was delivered last week for formulation and solubility testing by a major multinational corporation under a previously signed material transfer agreement.
One of the major differentiators between 1067 and Sirona’s earlier generation skin lightening compounds is that the chemical process of applying Sirona’s proprietary fluorination technology now requires only three steps to yield a final product. This results in a highly favourable cost of goods (COGs) and more importantly, a product with very profitable commercial viability. A preliminary estimation of COGs for the active ingredient yielded $0.10 CAD per 100 ml final formulation at a final concentration of 0.1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}.
Dr. Howard Verrico, CEO of Sirona Biochem, states, “Formulation testing on this quantity of compound represents a major milestone in the development of 1067, which will ultimately result in a successful licensing deal with one of the top cosmetic companies in the world.” He further stated, “This is the first time in Sirona’s history that we have advanced a cosmetic compound to formulation testing.”
Attila Hajdu, Chief Business Development Officer at Sirona Biochem, said, “Potential partners have replicated in vitro tests that we have done in the past to double-check our efficacy and safety data, and whatever else meets their needs to justify further collaboration. The request for formulation testing was a pleasant surprise for us because we originally anticipated that formulation work would occur after a licensing deal. This is a very exciting development.”
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Sirona Biochem
Sirona Biochem finishes scale-up of SBM-TFC-1067
Sirona Biochem (SBM.V) Reaches Major Milestone by Successful Scale-Up of Skin Lightening Compound SBM-TFC-1067
Formulation Testing by Potential Licensee Gets Underway Shortly
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB.DE), (the “Company“) is pleased to announce the successful scale-up of its skin lightening compound SBM-TFC-1067 (“1067“).
Sirona Biochem commissioned its contract research organization (CRO) Roowin (www.roowin.com) for the scale-up of 1 kg of 1067 compound. The successful scale-up represents a major scientific breakthrough by Sirona’s laboratory in Rouen, France. A quantity of 200 grams of 1067 was delivered last week for formulation and solubility testing by a major multinational corporation under a previously signed material transfer agreement.
One of the major differentiators between 1067 and Sirona’s earlier generation skin lightening compounds is that the chemical process of applying Sirona’s proprietary fluorination technology now requires only three steps to yield a final product. This results in a highly favourable cost of goods (COGs) and more importantly, a product with very profitable commercial viability. A preliminary estimation of COGs for the active ingredient yielded $0.10 CAD per 100 ml final formulation at a final concentration of 0.1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}.
Dr. Howard Verrico, CEO of Sirona Biochem, states, “Formulation testing on this quantity of compound represents a major milestone in the development of 1067, which will ultimately result in a successful licensing deal with one of the top cosmetic companies in the world.” He further stated, “This is the first time in Sirona’s history that we have advanced a cosmetic compound to formulation testing.”
Attila Hajdu, Chief Business Development Officer at Sirona Biochem, said, “Potential partners have replicated in vitro tests that we have done in the past to double-check our efficacy and safety data, and whatever else meets their needs to justify further collaboration. The request for formulation testing was a pleasant surprise for us because we originally anticipated that formulation work would occur after a licensing deal. This is a very exciting development.”
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
- Published in Blog, Business, Life Sciences
Affinor Growers announces resignation of Mr. Nick Brusatore as Executive Chairman, nomination of Brian Whitlock to the Board and Palisade Capital as Financial Consultant
Montreal (Canada), September 14, 2015 – Affinor Growers (CSE:AFI, OTC:RSSFF, Frankfurt:1AF) (“Affinor” or the “Corporation), a diversified agriculture and biotechnology company with proprietary vertical farming systems, announces the resignation of Mr. Nick Brusatore as the Executive Chairman of the Corporation, effective immediately.
Mr. Brusatore will continue to be a board member and will now dedicate his time as Affinor’s VP – Technology. The Corporation is presently in discussions and evaluating key candidates for the Chairman’s position.
Sebastien Plouffe, Affinor’s President and CEO, comments: “Nick was instrumental for the growth of the Company and at the present time I believe his new position as VP – Technology will be more helpful to achieve our business model. As the largest shareholder, we have no doubt that Nick will continue to do his best to bring the company to the success.”
Nick Brusatore comments: “I am excited about this change as I see my stepping down is a huge step forward for Affinor Growers, I am a mechanical designer and a grower of plants using sciences and have now completed our designs to help the world with automated food production vertical farming systems and now I look forward to launching it to the world.”
The Corporation also announces the nomination of Mr. Brian Whitlock as a new Board Member. Mr. Whitlock was already a shareholder of Affinor and he invested a significant amount in the recent private placement. Mr. Whitlock ran his own residential and commercial construction and development company for 18 years. Since 1999 he has been a Transportation Coordinator in the Vancouver Film and Television Industry. He also owns and manages his own fleet of film production vehicles. His detailed coordination of complex situations and superior management skills has proven him to be a leader in his field. He will definitely be helpful in Affinor’s logistic and with his experience in the industry, his advises shall be highly listened.Under the terms, Mr. Whitlock will receive 500,000 incentive stock options to purchase common shares. The options are exercisable on or before September 14, 2018, at an exercise price of 10 cents per share.
Finally, the Corporation is pleased to announce that Palisade Capital Corp. (“Palisade”) has been retained as the independent consultant to provide investor relations and marketing services, setting up marketing teleconferences and road shows for the European, Canadian and U.S. investment community, and assisting in the distribution of news releases. Collin Kettell and Sean Zubick, the principals of Palisade, will be primarily responsible for providing the marketing services to Affinor.
Palisade is an offshore merchant banking group, specializing in high-growth, small-cap investments. Through its global network of private equity groups, fund managers, high-net-worth and retail investors, Palisade is able to create strategic relationships to drive increased liquidity and source financing. (www.palisadecapitalcorp.com)
Sean Zubick, COO of Palisade commented, “We are very excited to work alongside the entire team at Affinor Growers to make 2015 and 2016 a major success. Vertical Farming has the potential to represent a major component of future food supply and Affinor has developed the technology to bring it to fruition.”
Effective September 15, 2015, the services agreement for investor relations and market making is for a term of 12 months for a fee of $8,400 per month. Palisade has been granted 300,000 options exercisable at 10 cents for a period of 3 years. Palisade subscribed for 3,000,000 units for an aggregate amount of $150,000 in Affinor’s financing completed last Friday.
About Affinor Growers Inc.
Affinor Growers is a diversified publicly traded company on the Canadian Securities Exchange under the symbol (“AFI”). Affinor is focused on growing high quality crops such as romaine lettuce, spinach, strawberries. Affinor is committed to becoming a pre-eminent grower, using exclusive vertical farming techniques.
On Behalf of the Board of Directors
AFFINOR GROWERS INC.
“Sebastien Plouffe”
President & CEO
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release
FORWARD LOOKING INFORMATION
This News Release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile onwww.sedar.com. This News Release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact Information:
Affinor Growers Inc.
Amanda Weber, Corporate Consultant
Phone: (604) 512-3230
Email: Amanda@affinorgrowers.com
Website:www.affinorgrowers.com
- Published in Affinor Growers
Sirona Biochem (SBM:tsxv) receives approval to trade on Xetra
SIRONA BIOCHEM APPOINTS GERMAN PRIVATE BANK HAUCK & AUFHAUSER AS DESIGNATED SPONSOR FOR XETRA(R)
Sirona Biochem Corp.’s (SBM:tsxv) shares have been accepted for continuous trading on the German electronic trading platform Xetra under the ticker symbol ZSB.DE. The International Security Identification Number (ISIN) is CA82967M1005.
The electronic trading system Xetratrademarkis utilized to trade approximately 300,000 international instruments. Xetratrademarkhas a market share of over 90 percent in equity trading and is one of the fastest trading systems in the world with a round-trip-time at only two milliseconds. Financial institutions, securities trading houses and brokers can participate in Xetratrademark trading. Xetratrademark operates independently of the trader’s location, permitting international participation. In fact, more than 130 participants from European countries outside Germany trade on Xetratrademark.
Sirona Biochem has appointed Hauck & Aufhauser Privatbankiers KGaA (H&A) as its designated sponsor on Xetratrademark. The designated sponsor will work to facilitate higher liquidity in stock trading of Sirona common shares by maintaining a constant quotation volume (minimum trade volume) to ensure tradability is guaranteed — even in highly volatile market periods.
Dr. Howard Verrico, CEO and Chairman of Sirona Biochem, stated, “The Xetratrademark listing marks a further step in Sirona’s commitment to its shareholders to enhance the liquidity of the Company’s common shares and is one of many initiatives we are taking to further increase market awareness. A generally visible valuation discount due to limited liquidity will be reduced and therefore should generate an increased interest of institutional investors. Several potential European investors have confirmed that a continuous Xetratrademark listing will make it easier for them to invest in Sirona. We are proud that, from our point of view, the best Xetratrademark specialist team in Germany has chosen Sirona as a new client.”About Hauck & Aufhauser Privatbankiers KGaA
Hauck & Aufhauser Privatbankiers is one of the few independent private banks in Germany and can look back on over 219 years of tradition. The bank resulted from the 1998 merger of two highly traditional private banks: Georg Hauck & Sohn Bankiers, founded in Frankfurt am Main in 1796, and Bankhaus H. Aufhauser, which opened its doors in Munich in 1870.
From its locations in Frankfurt am Main, Munich, Hamburg, Dusseldorf and Cologne, the bank focuses on providing comprehensive advisory services and administering the assets of its private, corporate and institutional clients. This includes asset management for institutional investors, close cooperation with independent asset managers and both the concept and management of private label funds.
The partners of the bank consist of the personally liable partner, Jochen Lucht, and the partners, Michael O. Bentlage and Stephan Rupprecht. All of the bank’s capital is in the hands of private investors. Hauck & Aufhauser considers itself a private bank that combines modernity with a strong sense of tradition. The focus of its business activities is on providing comprehensive and personalized advisory services, which form the basis for developing customized solutions. For more information visit: www.hauck-aufhaeuser.de.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit: www.sironabiochem.com.
- Published in Blog, Business, Life Sciences
Amana Signs Definitive Agreement With IWS
Amana firms up deal to buy Int’l Wastewater for $6.3MM
Amana Copper Ltd. has signed a definitive agreement dated Sept. 4, 2015, with International Wastewater Systems Inc. and its shareholders, pursuant to which Amana will acquire 100 per cent of the issued and outstanding common shares of IWS.
Pursuant to the terms of the definitive agreement, on closing of the transaction: (i) Amana will issue to the IWS shareholders a total of 45 million Amana common shares at a deemed price of 14 cents per consideration share for total aggregate consideration of $6.3-million; (ii) the resulting issuer will be renamed International Wastewater Systems Inc. and will continue the business of IWS, a world leader in waste water heat exchange technology; (iii) management of the resulting issuer will be led by Lynn Mueller, chairman and chief executive officer, and Yaron Conforti, chief financial officer, and the board of directors will comprise Mr. Mueller, Mr. Conforti, Mark McCooey and Paul Lee.
All consideration shares will be subject to escrow conditions and/or resale restrictions, as required by applicable securities laws and Canadian Securities Exchange requirements. The transaction will constitute a fundamental change for the company pursuant to the policies of the CSE. It is expected that the company will obtain shareholder approval of the transaction by way of a shareholder consent resolution. The completion of the transaction is subject to shareholder approval, and CSE and regulatory approvals.
Additional information concerning IWS and the transaction will be provided in a CSE listing statement, which will be made available on the company’s SEDAR profile.
InMed Appoints Paul Brennan as President & Chief Executive Officer
Vancouver, BC — September 03, 2015 – InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today, that Paul Brennan, a 25-year veteran of the life sciences industry has joined InMed as President & CEO, effective September 14, 2015. Mr. Brennan succeeds Craig Schneider who will remain on the board of directors.
Craig Schneider, Director, states, “We are extremely pleased that at this critical stage in the Company’s development, Mr. Brennan will be taking the helm of InMed and leading the Company through to its next clinical trials, financings and infrastructure buildout. Paul has extensive M&A, general management, financial, corporate and drug development expertise. We are fortunate to be under the leadership of an executive with broad global pharmaceutical development and commercialization experience with a proven track record of successfully bringing life science products to market on a global scale. We are pleased to bring his experience to bear on InMed’s operations as we make progress toward delivering meaningful therapies to underserved markets.”
Mr. Brennan was previously Senior Vice-President of Business Development at Arbutus Biopharma (formerly Tekmira Pharmaceuticals- NASDAQ). Previously he has held a number of senior management and consulting positions at biotech companies based in the U.S.and Canada. Mr. Brennan served as CEO of Altair Therapeutics, an emerging biopharmaceutical company based in San Diego, which focused on developing inhaled oligonucleotides for respiratory diseases. Prior to Altair, Mr. Brennan was Senior Vice President, Business Development at Aspreva Pharmaceuticals and was involved in the sale of Aspreva to Vifor Pharma for $915 million. Mr. Brennan was also employed at AnorMED where he held a number of roles including Acting President during which time he was involved in the sale of AnorMED to Genzyme for $580 million. Mr. Brennan has held senior positions in business development and regulatory affairs at AstraZeneca, where he worked in Sweden, the United Kingdom and Canada.
“I am excited for this opportunity and am excited to lead our talented and dedicated team. InMed’s corporate strategy, strong pipeline and innovative development programs, provides a solid basis for long-term value. I am passionate about our prospects, and look forward to working for the benefit of patients, physicians, and shareholders as we advance our products through the clinic and into the market to deliver innovative and efficacious products.”
Mr. Brennan earned his B.Sc. in Life Sciences and his M.Sc. in Physiology from Queen’s University, in Kingston, Ontario.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
For more information, visit www.inmedpharma.com
Contact: InMed Pharmaceuticals Inc.
Craig Schneider
President and Chief Executive Officer
T: 604.669.7207
E: craig@inmedpharma.com
Investors:
Chris Bogart
SVP, Corporate Strategy and Investor Relations
T: 604.669.7207
E: chris@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about Mr. Brennan acting as President and CEO of the Company; Mr. Schneider remaining on the board of directors; and the fundamental value drivers of the company. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: Mr. Brennan’s continued ability to serve as President and CEO; Mr. Schneider’s continued ability to serve as a director; continued demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: the possibility that Mr. Brennan will no longer be willing or able to serve as President and CEO; the possibility that Mr. Schneider will no longer be willing or able to serve as a director; InMed’s proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value; and economic or market conditions may worsen.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
- Published in InMed Pharmaceuticals